Literature DB >> 8990130

Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.

J J Pei1, T Tanaka, Y C Tung, E Braak, K Iqbal, I Grundke-Iqbal.   

Abstract

A number of studies have implicated a proline-directed protein kinase, glycogen synthase kinase-3 (GSK-3) in the hyperphosphorylation of tau in Alzheimer's disease (AD). Toward understanding the role of GSK-3 in the abnormal hyperphosphorylation of tau in AD we have found that GSK-3 is prominently present in neuronal cell bodies and their processes and co-localizes with neurofibrillary changes in AD brain. Furthermore, the levels of GSK-3 as determined by indirect ELISA are approximately 50% increased in the postsynaptosomal supernatant from AD brains as compared to the controls. However, no increase in GSK-3 enzyme activity was detected. In AD brain, with its reduced phosphatase activity, even normal levels of GSK-3 activity might be sufficient for the hyperphosphorylation of tau.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8990130     DOI: 10.1097/00005072-199701000-00007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  106 in total

1.  Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments.

Authors:  Juan Hu; He-Zhou Huang; Xiang Wang; Ao-Ji Xie; Xiong Wang; Dan Liu; Jian-Zhi Wang; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2014-11-05       Impact factor: 5.590

2.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

3.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

4.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

Authors:  Wendy Noble; Emmanuel Planel; Cindy Zehr; Vicki Olm; Jordana Meyerson; Farhana Suleman; Kate Gaynor; Lili Wang; John LaFrancois; Boris Feinstein; Mark Burns; Pavan Krishnamurthy; Yi Wen; Ratan Bhat; Jada Lewis; Dennis Dickson; Karen Duff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

5.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

6.  Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments.

Authors:  Ling-Qiang Zhu; Shao-Hui Wang; Dan Liu; Yang-Yang Yin; Qing Tian; Xiao-Chuan Wang; Qun Wang; Jian-Guo Chen; Jian-Zhi Wang
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

7.  Physiological regulation of tau phosphorylation during hibernation.

Authors:  Bo Su; Xinglong Wang; Kelly L Drew; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

Review 8.  Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence.

Authors:  Koji Tomobe; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2009-02-27       Impact factor: 3.996

9.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

10.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.